Furthermore, SETD2 loss correlated with reduced CD8<sup>+</sup> T cell infiltration and increased regulatory T cell presence.<h4>Conclusion</h4>This meta-analysis identifies SETD2 as an epigenetic regulator linking tumor metabolic reprogramming to antitumor immunity. The gene discussed is CD8A; the disease is neoplasm.